Radiofrequency Ablation for Stage I Non-Small Cell Lung Cancer: An Updated Review of Literature from the Last Decade

Yusuke Matsui; Toshihiro Iguchi; Koji Tomita; Mayu Uka; Jun Sakurai; Hideo Gobara; Susumu Kanazawa

doi:10.22575/interventionalradiology.2020-0007

Radiofrequency Ablation for Stage I Non-Small Cell Lung Cancer: An Updated Review of Literature from the Last Decade

Interv Radiol (Higashimatsuyama). 2020 Jun 10;5(2):43-49. doi: 10.22575/interventionalradiology.2020-0007. eCollection 2020 Jun 30.

Authors

Yusuke Matsui¹, Toshihiro Iguchi¹, Koji Tomita¹, Mayu Uka¹, Jun Sakurai², Hideo Gobara³, Susumu Kanazawa¹

Affiliations

¹ Department of Radiology, Okayama University Medical School, Okayama, Japan.
² Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
³ Department of Medical Informatics, Okayama University Hospital, Okayama, Japan.

PMID: 36284655
PMCID: PMC9550390
DOI: 10.22575/interventionalradiology.2020-0007

Abstract

This review summarizes the current findings on radiofrequency ablation (RFA) for stage I non-small cell lung cancer (NSCLC) from relevant literature published in the last decade. While most earlier studies included small populations and had short follow-up periods, more robust data have become available owing to prospective or large cohort studies. The reported overall survival rates after RFA for stage I NSCLC were 83-96%, 40-74%, and 23-61% at 1, 3, and 5 years, respectively, in recent studies. Furthermore, many comparative studies on the outcomes of RFA and stereotactic body radiotherapy have been performed. Most of these studies report no significant difference in survival outcomes between the therapies. Currently, major guidelines define RFA as a reasonable alternative treatment for stage I NSCLC in non-surgical candidates.

Keywords: early stage; non-small cell lung cancer; radiofrequency ablation; stereotactic body radiotherapy; survival.

Publication types

Review